Testing a new treatment for lymphoma that has spread to the brain
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding the drug zanubrutinib to standard chemotherapy can better treat newly diagnosed diffuse large B-cell lymphoma that has spread to the central nervous system. It is for patients whose lymphoma is identified by a specific molecular subtype or by positive findings in the spinal fluid or brain scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with diffuse large B-cell lymphoma that has not been treated before, and it has spread to your brain or spinal cord.
- You are generally able to care for yourself (ECOG score 0-3).
- Your blood counts, liver, and kidney function are within certain limits.
- You have not had any prior chemotherapy, radiation, or targeted therapy for this lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests combining a targeted drug (orelabrutinib) with standard chemo (R-CHOP plus methotrexate or thiotepa) for people whose DLBCL has spread to the brain or spinal cord. The goal is to see if this combination works better against hard-to-treat lymphoma.
This trial tests a combination of targeted therapy (zanubrutinib) plus a standard chemo-immunotherapy regimen (pola-R-CHP) and high-dose methotrexate for people whose large B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this approach can effectively treat lymphoma in both the body and the central nervous system.
This trial tests a new drug, zanubrutinib, combined with standard chemotherapy for people recently diagnosed with primary central nervous system lymphoma (a type of brain cancer). It aims to see if this combination is safe and effective.
This Phase 2 study tests whether adding intrathecal methotrexate (a cancer drug delivered into the spinal fluid) to standard chemo can lower the risk of diffuse large B-cell lymphoma (DLBCL) coming back in the brain or spinal fluid. It is for people with higher-than-usual risk of central nervous system (CNS) relapse.
Hear when a new Diffuse Large B Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.